Treatment Access Solution
A donation from Bristol-Myers Squibb
Bristol-Myers Squibb has made a donation to The Max Foundation to increase access to Sprycel™ (dasatinib) for people living with chronic myeloid leukemia (CML) in specified low income countries. This access pathway is specifically designed to respond to spontaneous requests for treatment access on behalf of patients who are uninsured and underinsured, where product is either not available commercially, where significant access hurdles exist and where local market initiatives cannot enable access to the therapy.
Requests for Sprycel™ (dasatinib) must meet established criteria. View our global map and click on individual countries to learn where this initiative is operating today. Contact us for more information about access to Sprycel™ (dasatinib) in these countries.